{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:59:03Z","timestamp":1783483143357,"version":"3.55.0"},"reference-count":36,"publisher":"Wiley","issue":"17","license":[{"start":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T00:00:00Z","timestamp":1400544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>In a previous phase 2 trial, axitinib was active and well tolerated in patients with advanced thyroid cancer. In this second phase 2 trial, the efficacy and safety of axitinib were evaluated further in this population, and pharmacokinetic\/pharmacodynamic relationships and patient\u2010reported outcomes were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Patients (N\u2009=\u200952) with metastatic or unresectable, locally advanced medullary or differentiated thyroid cancer that was refractory or not amenable to iodine\u2010131 received a starting dose of axitinib 5 mg twice daily. The primary endpoint was the objective response rate (ORR). Secondary endpoints included progression\u2010free survival (PFS), overall survival (OS), safety, pharmacokinetic parameters, and patient\u2010reported outcomes assessed with the MD Anderson Symptom Inventory questionnaire.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The overall ORR was 35% (18 partial responses), and 18 patients had stable disease for \u226516 weeks. The median PFS was 16.1 months, and the median OS was 27.2 months. All\u2010causality, grade \u22653 adverse events (&gt;5%) were fatigue, dyspnea, diarrhea, decreased weight, pain in extremity, hypertension, decreased appetite, palmar\u2010plantar erythrodysesthesia, hypocalcemia, and myalgia. Patients who had greater axitinib exposure had a longer median PFS. Quality of life was maintained during treatment with axitinib, and no significant deterioration in symptoms or interference in daily life caused by symptoms, assessed on MD Anderson Symptom Inventory subscales, were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Axitinib has activity and a manageable safety profile while maintaining quality of life, and it represents an additional treatment option for patients with advanced thyroid cancer. <jats:bold><jats:italic>Cancer<\/jats:italic> 2014;120:2694\u20132703.<\/jats:bold> \u00a9 <jats:italic>2014 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.28766","type":"journal-article","created":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T16:37:02Z","timestamp":1400603822000},"page":"2694-2703","source":"Crossref","is-referenced-by-count":104,"title":["Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic\/pharmacodynamic and quality\u2010of\u2010life assessments"],"prefix":"10.1002","volume":"120","author":[{"given":"Laura D.","family":"Locati","sequence":"first","affiliation":[{"name":"Head and Neck Medical Oncology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Licitra","sequence":"additional","affiliation":[{"name":"Head and Neck Medical Oncology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Agate","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Clinical and Experimental Medicine, University of Pisa Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai\u2010Hong I.","family":"Ou","sequence":"additional","affiliation":[{"name":"Chao Family Comprehensive Cancer Center\u2010University of California Irvine Medical Center Orange California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andree","family":"Boucher","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Montreal Hospital Center Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Jarzab","sequence":"additional","affiliation":[{"name":"Oncology Center, Marii Sklodowskiej\u2010Curie Institute Gliwice Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shukui","family":"Qin","sequence":"additional","affiliation":[{"name":"Nanjing Bayi Hospital Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine A.","family":"Kane","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center Aurora Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori J.","family":"Wirth","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dana\u2010Farber Cancer Institute Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Chen","sequence":"additional","affiliation":[{"name":"Pfizer Oncology New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinil","family":"Kim","sequence":"additional","affiliation":[{"name":"Pfizer Oncology San Diego California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Ingrosso","sequence":"additional","affiliation":[{"name":"Pfizer Oncology Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazdi K.","family":"Pithavala","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Pfizer Oncology San Diego California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bycott","sequence":"additional","affiliation":[{"name":"Pfizer Oncology San Diego California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezra E. W.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago Medical Center Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,5,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-008-9260-4"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25516"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2008.0281"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20141"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2838"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1610041"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0129"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70203-5"},{"key":"e_1_2_7_10_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.5547","article-title":"Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC) [abstract]","volume":"30","author":"Cabanillas ME","year":"2012","journal-title":"J Clin Oncol."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0994"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9566"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4659"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.3279"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.2717"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.4145"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70335-2"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.7815"},{"key":"e_1_2_7_19_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.5508","article-title":"An international, double\u2010blind, randomized, placebo\u2010controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline [abstract]","volume":"30","author":"Schoffski P","year":"2012","journal-title":"J Clin Oncol."},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa075853"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5040"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.12.96"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0520"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0652"},{"key":"e_1_2_7_25_1","volume-title":"Inlyta (axitinib) [prescribing information]","author":"Pfizer Inc","year":"2012"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_2_7_27_1","unstructured":"Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events Version 3.0. Bethesda MD: National Cancer Institute; 2006. Available at:http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf. Accessed September 27 2013."},{"key":"e_1_2_7_28_1","unstructured":"CleelandCS. The MD Anderson Symptom Inventory User Guide: June 25 2013 [draft]. Houston TX: The University of Texas MD Anderson Cancer Center; 2013. Available at:http:\/\/www.mdanderson.org\/education\u2010and\u2010research\/departments\u2010programs\u2010and\u2010labs\/departments\u2010and\u2010divisions\/symptom\u2010research\/symptom\u2010assessment\u2010tools\/MDASI_userguide.pdf. Accessed November 6 2013."},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.73"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70093-7"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2806"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61613-9"},{"key":"e_1_2_7_33_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.18_suppl.4","article-title":"Sorafenib in locally advanced or metastatic patients with radioactive iodine\u2010refractory differentiated thyroid cancer: the phase III DECISION trial [abstract]","volume":"31","author":"Brose MS","year":"2013","journal-title":"J Clin Oncol."},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm324"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2011.0139"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2012.741326"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/08858190802247762"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.28766","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.28766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:07:11Z","timestamp":1760274431000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.28766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,20]]},"references-count":36,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1002\/cncr.28766"],"URL":"https:\/\/doi.org\/10.1002\/cncr.28766","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,20]]}}}